Get started
Author

Michael Teufel

Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial
2019 · Matthew Smith, Chris Parker, et al. · The Lancet Oncology · 413
Sequence Identification and Characterization of Human Carnosinase and a Closely Related Non-specific Dipeptidase
2003 · Michael Teufel, Vladimir Saudek, et al. · Journal of Biological Chemistry · 346
Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial
2015 · Josep Tabernero, Heinz-Josef Lenz, et al. · The Lancet Oncology · 329
PDF
Evidence that HIV‐1 Rev directly promotes the nuclear export of unspliced RNA.
1994 · U. Fischer, S. Meyer, et al. · The EMBO Journal · 246
Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma
2019 · Michael Teufel, Henrik Seidel, et al. · Gastroenterology · 202
PDF
Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma
2018 · Ho Yeong Lim, Philippe Merle, et al. · Clinical Cancer Research · 81
PDF
Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma
2017 · Maria Kissel, Sandra Berndt, et al. · Oncotarget · 62
PDF
Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer
2016 · Jean-Luc Van Laethem, Hanno Riess, et al. · Targeted Oncology · 59
Rev-mediated nuclear export of RNA is dominant over nuclear retention and is coupled to the Ran-GTPase cycle
1999 · U. Fischer, V. W. Pollard, et al. · Nucleic Acids Research · 49
Solution structure of a neurotrophic ligand bound to FKBP12 and its effects on protein dynamics
2000 · Christian Sich, Sabina Improta, et al. · European Journal of Biochemistry · 44
Identification and characterisation of carnostatine (SAN9812), a potent and selective carnosinase (CN1) inhibitor with in vivo activity
2018 · Jiedong Qiu, Sibylle J. Hauske, et al. · Amino Acids · 41
PDF
Phase 1 dose-escalation and pharmacokinetic study of regorafenib in paediatric patients with recurrent or refractory solid malignancies
2021 · Birgit Geoerger, Bruce Morland, et al. · European Journal of Cancer · 29
PDF
Properties of bacteriorhodopsin derivatives constructed by insertion of an exogenous epitope into extra‐membrane loops.
1993 · M. Teufel, M. Pompejus, et al. · The EMBO Journal · 28
Correction to: Properties of bacteriorhodopsin derivatives constructed by insertion of an exogenous epitope into extra‐membrane loops.
1994 · M. Teufel, M. Pompejus, et al. · The EMBO Journal · 27
PDF
Molecular subtypes and outcomes in regorafenib-treated patients with metastatic colorectal cancer (mCRC) enrolled in the CORRECT trial.
2015 · Michael Teufel, Susanne Schwenke, et al. · Journal of Clinical Oncology · 26
Properties of Sialidase Isolated fromActinomyces viscosusDSM 43798
1989 · Michael TEUFEL, Peter ROGGENTIN, et al. · Biological Chemistry Hoppe-Seyler · 25
Brightline-2: a phase IIa/IIb trial of brigimadlin (BI 907828) in advanced biliary tract cancer, pancreatic ductal adenocarcinoma or other solid tumors
2024 · Changhoon Yoo, Angela Lamarca, et al. · Future Oncology · 20
Efficacy and Safety of the MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case Series
2024 · Noboru Yamamoto, Anthony Tolcher, et al. · OncoTargets and Therapy · 17
PDF
High‐yield production of bacteriorhodopsin via expression of a synthetic gene in Escherichia coli
1993 · Markus POMPEJUS, Karlheinz FRIEDRICH, et al. · European Journal of Biochemistry · 15
Phase II study of refametinib (BAY 86-9766), an allosteric dual MEK 1/2 inhibitor, and gemcitabine in patients with unresectable, locally advanced, or metastatic pancreatic cancer.
2014 · Jean-Luc Van Laethem, Jacek Jassem, et al. · Journal of Clinical Oncology · 12
Efficacy of regorafenib (REG) in patients with hepatocellular carcinoma (HCC) in the phase III RESORCE trial according to alpha-fetoprotein (AFP) and c-Met levels as predictors of poor prognosis.
2017 · Michael Teufel, Karl Köchert, et al. · Journal of Clinical Oncology · 10
Broad spectrum of regorafenib activity on mutant KIT and absence of clonal selection in gastrointestinal stromal tumor (GIST): correlative analysis from the GRID trial
2022 · Michael Jeffers, Christian Kappeler, et al. · Gastric Cancer · 9
PDF
Analysis of plasma protein biomarkers from the phase 3 CONCUR study of regorafenib in Asian patients with metastatic colorectal cancer (mCRC).
2016 · Michael Teufel, Joachim Kalmus, et al. · Journal of Clinical Oncology · 9
PD-003 Analysis of single-nucleotide polymorphisms (SNPs) in the phase 3 CORRECT trial of regorafenib vs placebo in patients with metastatic colorectal cancer (mCRC)
2016 · D. Lambrechts, K. Koechert, et al. · Annals of Oncology · 8
Exploratory analysis of baseline microsatellite instability (MSI) status in patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) or placebo in the phase 3 CORRECT trial
2017 · K. Köchert, G. Beckmann, et al. · Annals of Oncology · 7
Works count: 45
Citation count: 2,140
H-index: 17
I10-index: 21
Year
Topic
Type